HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enforma Carb Trapper Plus Supplement Ad Claims Under FTC Scrutiny

This article was originally published in The Tan Sheet

Executive Summary

Enforma Natural Products could be hit with civil contempt charges for the third time if FTC determines the firm is making unsubstantiated advertising and marketing claims for its Carb Trapper Plus weight-loss product

You may also be interested in...



Weight-Loss Product Manufacturers Receive FTC Rebuke

A Federal Trade Commission settlement with the makers of Exercise in a Bottle and Fat Trapper barring the firms from marketing weight-loss products in the future is an example of the agency's willingness to deliver severe punishments against repeat offenders

FTC v. Enforma

Supplement firm preliminarily enjoined from making certain weight-loss claims for Chitozyme and Acceleron under Los Angeles federal Judge Spencer Letts' Oct. 30 order. FTC says Enforma must recall, repackage and relabel products while also ensuring vendors are in compliance. Enforma is seeking stay of the preliminary injunction pending appeal. FTC now is expected to seek similar injunctive relief for Enforma's Fat Trapper Plus and Exercise In A Bottle. Court's order stems from FTC's July 23 civil contempt motion (1"The Tan Sheet" Aug. 5, 2002, p. 5)...

Enforma contests FTC allegations

Pointing to 19 studies as evidence of its Chitozyme weight-loss supplement's efficacy, company says FTC's recent contempt motion is "frivolous" and commission will be unable to provide clear and convincing evidence that Enforma lacks adequate substantiation for its ad claims. Enforma asserts FTC is using an undefined standard for "competent and reliable scientific evidence" and suggests commission should clarify this standard by telling Enforma what studies it considers vital to marketing Chitozyme. Firm says it has turned over to FTC studies on Carb Trapper Plus, and notes its products carry money-back guarantees, thereby refuting FTC's claim that consumers have suffered financial harm (1"The Tan Sheet" Aug. 5, 2002, p. 5). Enforma says it is considering suing FTC if company prevails in present action. Hearing on FTC's contempt motion, preliminary injunction request is scheduled for Sept. 30...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel